TRIZAL study: switching from successful HAART to TrizivirTM (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results

This publication has 14 references indexed in Scilit:

• HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study
  AIDS, 2001
• Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA
  AIDS, 2001
• Abacavir-Lamivudine-Zidovudine vs Indinavir-Lamivudine-Zidovudine in Antiretroviral-Naive HIV-Infected AdultsA Randomized Equivalence Trial
  JAMA, 2001
• Effects of Protease Inhibitors on Hyperglycemia, Hyperlipidemia, and Lipodystrophy
  Archives of internal medicine (1960), 2000
• Hyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV Infection
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
• HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy
  AIDS, 1999
• Incidence of Discontinuation of Highly Active Antiretroviral Combination Therapy (HAART) and Its Determinants
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
• Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
  The Lancet, 1999
• Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection
  AIDS, 1998
• Potential factors affecting adherence with HIV therapy
  AIDS, 1997